Inhibikase Therapeutics Inc’s filing revealed that its 10% Owner Sands Capital Life Sciences Pu acquired Company’s shares for reported $3.0 million on Nov 21 ’25. In the deal valued at $1.45 per share,2,068,965 shares were bought. As a result of this transaction, Sands Capital Life Sciences Pu now holds 13,018,965 shares worth roughly $26.04 million.
H.C. Wainwright initiated its Inhibikase Therapeutics Inc [IKT] rating to a Buy in a research note published on December 26, 2025; the price target was $8. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in mid December with a ‘”an Overweight”‘ rating. H.C. Wainwright also remained covering IKT and has decreased its forecast on February 12, 2025 with a “Neutral” recommendation from previously “Buy” rating.
Price Performance Review of IKT
On Friday, Inhibikase Therapeutics Inc [NASDAQ:IKT] saw its stock jump 21.21% to $2.0. Over the last five days, the stock has gained 19.76%. Inhibikase Therapeutics Inc shares have fallen nearly -32.43% since the year began. Nevertheless, the stocks have fallen -38.46% over the past one year. While a 52-week high of $3.49 was reached on 01/02/25, a 52-week low of $1.33 was recorded on 11/03/25.
Levels Of Support And Resistance For IKT Stock
The 24-hour chart illustrates a support level at 1.79, which if violated will result in even more drops to 1.57. On the upside, there is a resistance level at 2.13. A further resistance level may holdings at 2.26.
How much short interest is there in Inhibikase Therapeutics Inc?
A steep rise in short interest was recorded in Inhibikase Therapeutics Inc stocks on 2025-12-15, growing by 2.26 million shares to a total of 5.35 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 3.09 million shares. There was a rise of 42.28%, which implies that there is a positive sentiment for the stock.
